Michael Dybbs - Dimension Therapeutics Independent Director

Director

Dr. Michael Dybbs, Ph.D. is an Independent Director of the Company. Dybbs has served as a member of our board of directors since April 2015. Dr. Dybbs is currently a Managing Member of Samsara BioCapital GP, LLC. Prior to that Dr. Dybbs was a partner at New Leaf Venture Partners, L.L.C., where he worked from 2009 to 2016. Prior to joining New Leaf Venture Partners, L.L.C., Dr. Dybbs was a principal at the Boston Consulting Group where he worked from 2005 to 2009. Dr. Dybbs has served as a director of Versartis, Inc. and numerous private life sciences companies since 2015.
Age 41
Tenure 9 years
Professional MarksPh.D
Phone617 401-0011
Webwww.dimensiontx.com
Dybbs received an A.B. in biochemical sciences from Harvard College and a Ph.D. in molecular biology from U.C. Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship. We believe that Dr. Dybbs is qualified to serve on our board of directors due to his experience in the life sciences industry and the VC industry, and his leadership and management experience.

Dimension Therapeutics Management Efficiency

Dimension Therapeutics' management efficiency ratios could be used to measure how well Dimension Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 5.78 M in liabilities with Debt to Equity (D/E) ratio of 16.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Dimension Therapeutics has a current ratio of 3.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Dimension Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Dimension Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dimension Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dimension to invest in growth at high rates of return. When we think about Dimension Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Randolph PeelerNational Vision Holdings
53
Paul CappuccioChipotle Mexican Grill
57
Kimbal MuskChipotle Mexican Grill
45
Malcolm WallNational Vision Holdings
57
Patrick FlynnChipotle Mexican Grill
72
Leslie KeatingSunOpta
57
Ali NamvarChipotle Mexican Grill
50
Joseph LevatoThe Wendys Co
77
Drew ThomsonNational Vision Holdings
44
Felix GernburdNational Vision Holdings
30
Matthew PeltzThe Wendys Co
35
Neil FlanzraichChipotle Mexican Grill
76
Thomas TaylorNational Vision Holdings
52
Gary RodkinSimon Property Group
68
Robert SleddPool Corporation
65
Randolph LewisThe Wendys Co
64
Larry KayDine Brands Global
73
Terence LeahyNational Vision Holdings
59
Shan AtkinsSunOpta
59
Stephen GillettChipotle Mexican Grill
39
Robin HickenlooperChipotle Mexican Grill
42
Dimension Therapeutics, Inc., a gene therapy platform company, focuses on discovering and developing therapeutic solutions for people living with rare diseases associated with the liver and caused by genetic mutations. Dimension Therapeutics (DMTX) is traded on NASDAQ Exchange in USA and employs 53 people.

Management Performance

Dimension Therapeutics Leadership Team

Elected by the shareholders, the Dimension Therapeutics' board of directors comprises two types of representatives: Dimension Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dimension. The board's role is to monitor Dimension Therapeutics' management team and ensure that shareholders' interests are well served. Dimension Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dimension Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Mary Thistle, Chief Business Officer
Michael Dybbs, Independent Director
Stephanie Haller, Vice President - Clinical Operations
George Migausky, Independent Director
Reed Clark, Sr. VP of Pharmaceutical Devel.
Ben Auspitz, Chairman of the Board, Co-Founder
Georges Gemayel, Independent Director
Alan Colowick, Independent Director
Rishi Gupta, Independent Chairperson of the Board
Sam Wadsworth, Chief Scientific Officer
Jean Franchi, CFO and Treasurer
Samuel Wadsworth, Chief Scientific Officer
MRCP MBBS, CEO and President and Director
Arlene Morris, Independent Director
Eric MD, Chief Medical Officer
Annalisa Jenkins, CEO, Director
John Hohneker, Director
Eric Crombez, Chief Medical Officer

Dimension Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dimension Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Dimension Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dimension Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dimension Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Principal Financial could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Principal Financial when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Principal Financial - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Principal Financial Group to buy it.
The correlation of Principal Financial is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Principal Financial moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Principal Financial moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Principal Financial can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Consideration for investing in Dimension Stock

If you are still planning to invest in Dimension Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dimension Therapeutics' history and understand the potential risks before investing.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Global Correlations
Find global opportunities by holding instruments from different markets
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance